# PRESS RELEASE 2025

# [With two in five employees undergoing fertility treatment leaving their jobs or considering quitting, are companies doing enough?](/content/with-two-in-five-employees-undergoing-fertility-treatment-leaving-their-jobs-or-considering-quitting-are-companies-doing-enough/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 26 November 2025

With two in five employees undergoing fertility treatment leaving their jobs or…

# [Ferring Pharmaceuticals to explore strategic options for Rebyota®](/content/ferring-pharmaceuticals-to-explore-strategic-options-for-rebyota/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 29 October 2025

# [Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec](/content/ferring-japan-announces-pmda-acceptance-of-nda-filing-for-nadofaragene-firadenovec/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 11 September 2025

# [Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients](/content/ferring-pharmaceuticals-announces-results-of-the-iris-study-a-comparative-analysis-of-individualised-vs-conventional-recombinant-follicular-stimulating-hormone-dosing-in-indian-infertile-patients/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 03 May 2025

Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of…

# [U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)](/content/u-s-fda-approves-second-drug-product-manufacturing-facility-for-adstiladrin-nadofaragene-firadenovec-vncg/index.html)

By [siddhant](/content/author/siddhant/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 24 April 2025

U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)…

# [Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC patients](/content/ferring-announces-initial-data-from-phase-3-trial-in-japanese-patients-demonstrating-75-complete-response-rate-at-3-months-with-nadofaragene-firadenovec-in-bcg-unresponsive-nmibc-patients/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 21 April 2025

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating…

# [Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin](/content/ferring-achieved-record-sales-driven-by-reproductive-medicine-combined-with-the-emergence-of-adstiladrin/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2025](/content/category/press-release-2025/index.html) on 09 April 2025

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence…